| ABSTRACT Objective:To analysis clinical features and resistance of producing ESBLs Escherichia coli of 0 14 years inpatients in a grade a tertiary hospital, and to provide the basis for guiding clinical rational use of antimicrobial agents.Methods: Clinical data of producing ESBLs Escherichia coli, diagnosed in our hospital neonatal and pediatric inpatient from January 2013 to December 2015, including the distribution department, source of specimen, the number of strain, the positive rate and resistance rates, were collected and analyzed. Results:A totle of 1 187 strains of Escherichia coli were cultured from patients, in which 555 (46.76%) strains were producing ESBLs, in three years. Constituent ratio of producing ESBLs Escherichia coli was 45.18%, 54.04%, 44.20% respectively in 2013 2015.In 2013 2014, NICU and PICU were the highest positive rate in all pediatric ward, the positive rate was up to 95% to 100%, but significantly decreased to around 63% in 2015. The main source of specimen strain producing ESBLS order was sputum>urine>blood>other. The children's respiratory medicine, urology and PICU were top three distribution departments. Production ESBLs Escherichia coli showed high level resistance to commonly used antibiotics, resistance rates of penicillins and cephalosporins were more than 85%, resistance rates of ceftazidime, aztreonam, trimethoprim sulfamethoxazole, ampicillin/sulbactam, gentamicin were more than 30%,resistance rates of cefepime was less than 20%, resistance rates of piperacillin/tazobactam, cefotetan, amikacin, carbapenems were less than or equal to 3%. Conclusion:Producing ESBLs Escherichia coli were widely distributed in pediatric ward. Some pediatric ward positive rate is still high, and sensitive to carbapenems, head of ADM. It should be rational use antibiotics in clinical. |
